RCUS Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Arcus Biosciences Inc (RCUS) is not a strong buy at the moment for a beginner, long-term investor with $50,000-$100,000 available. The stock lacks immediate positive catalysts, has mixed analyst sentiment, and faces potential headwinds in its pipeline. While the company has a promising product in Casdatifan, the recent downgrades and halted trials raise concerns. A hold is recommended until clearer positive developments emerge.
The MACD is positive and expanding, suggesting slight bullish momentum. However, the RSI is neutral at 44.266, and the moving averages are converging, indicating no clear trend. The pre-market price is $19.29, below the pivot level of $19.861, with support at $18.69 and resistance at $21.031. This suggests the stock is trading near a support zone but lacks strong upward momentum.
Hedge funds are increasing their positions significantly, with a 186.42% increase in buying over the last quarter. Casdatifan remains a potential multi-billion-dollar opportunity with multiple catalysts expected in 2026.
The late-stage anti-TIGIT cancer drug trial was halted, eliminating a key near-term catalyst. Analysts have downgraded the stock, citing headwinds from upcoming data readouts and unclear differentiation for Welireg. Revenue declined 8.3% YoY in Q4, and EPS dropped 13.59% YoY.
In Q4 2025, the company reported revenue of $33 million, an 8.3% YoY decline but above expectations. Net income improved by 12.77% YoY to -$106 million, but EPS dropped 13.59% YoY to -$0.89. Gross margin remained at 100%.
Analyst sentiment is mixed to negative. Wells Fargo and Morgan Stanley downgraded the stock to Equal Weight, citing headwinds and balanced risk/reward. H.C. Wainwright and Truist lowered price targets but maintained Buy ratings, focusing on the potential of Casdatifan. Citi also lowered its price target but remains optimistic about Casdatifan's future.
